Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Veru (NASDAQ: VERU) announced that Chairman, President and CEO Mitchell Steiner, M.D., will participate in a fireside chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 12, 2026, from 2:00–2:25 p.m. EDT. A live and archived webcast will be available in the Investors section of Veru’s website.
Veru highlighted its obesity program evaluating enobosarm with GLP‑1 receptor agonists. The Phase 2b PLATEAU study in approximately 200 older patients with obesity is fully enrolled, with interim DXA results expected in Q1 2027 and topline data in Q4 2027. Veru also noted positive results from the completed Phase 2b QUALITY and maintenance extension study, which evaluated enobosarm plus semaglutide and then enobosarm monotherapy for weight management outcomes in older patients.
Veru (NASDAQ: VERU) reported full enrollment, exceeding its target of 200 patients, in the Phase 2b PLATEAU trial evaluating oral enobosarm 3 mg versus placebo in older patients (≥65 years) with obesity (BMI ≥35) who are starting semaglutide for weight reduction. The double-blind, placebo-controlled study will assess effects on total body weight, fat mass, lean mass, physical function, bone mineral density, and safety over 68 weeks.
According to Veru, interim DXA-based results on lean and fat mass after 32 weeks are expected in calendar Q1 2027, with final topline data anticipated in Q4 2027. The company highlights prior positive Phase 2b QUALITY data, where enobosarm plus semaglutide preserved lean mass and physical function, increased fat loss over 16 weeks, and enobosarm monotherapy helped prevent weight regain after GLP-1 RA discontinuation.
Veru (NASDAQ: VERU) will present at the 2026 4th Annual Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day in Boston on July 14-16, 2026.
Company leaders will discuss geriatric sarcopenic obesity therapies and evolving obesity drug development endpoints.
Veru (NASDAQ:VERU) reported fiscal 2026 Q2 results and progress in its enobosarm obesity program. Research and development expenses fell to $3.1 million from $3.9 million, and general and administrative expenses to $4.1 million from $5.2 million.
Operating loss from continuing operations decreased to $7.2 million from $8.1 million, and net loss to $2.7 million, or $0.12 per share, from $7.9 million, or $0.54 per share. Cash rose to $27.6 million from $15.8 million. The Phase 2b PLATEAU trial in older obese patients on semaglutide is actively enrolling, with interim DXA-based data expected in early 2027 and topline data in late 2027, building on positive Phase 2b QUALITY results.
Veru (NASDAQ: VERU) will report fiscal 2026 second quarter financial results and provide a business update on Wednesday, May 13, 2026 at 8:00 a.m. ET. The company will host a conference call and audio webcast; replay options will be available online and by telephonic replay.
Access the live webcast and archived replay via the Home or Investors page at verupharma.com. Telephone dial-in numbers and replay passcode are provided for domestic and international callers.
Veru (NASDAQ: VERU) enrolled the first patient in the Phase 2b PLATEAU trial testing oral enobosarm 3mg plus injectable semaglutide in ~200 older patients (age ≥65, BMI ≥35) with obesity to preserve lean mass, physical function and bone while augmenting fat and weight loss.
An interim DXA analysis is expected in Q1 2027 (34 weeks) and final topline data in Q4 2027 (primary endpoint: percent change in total body weight at 68 weeks).
Veru (NASDAQ: VERU) announced that Mitchell Steiner, M.D., Chairman, President and CEO, will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 from 3:20 pm to 3:50 pm ET.
A live webcast will be accessible via the company website and an archived webcast will be posted after the event.
Veru (NASDAQ: VERU) reported Q1 fiscal 2026 results and clinical updates. Cash was $33.0M as of Dec 31, 2025. Operating loss improved to $5.4M and net loss was $5.3M ($0.26/share).
Veru plans a ~200-patient Phase 2b PLATEAU trial of enobosarm plus semaglutide starting Q1 2026 with an interim analysis planned Q1 2027; FDA provided regulatory pathways including a 5% placebo-corrected weight-loss benchmark or alternative functional/BMD benefits.
Veru (NASDAQ: VERU) will report fiscal 2026 first quarter results and host a conference call and audio webcast on Wednesday, February 11, 2026 at 8:00 a.m. ET.
The webcast is accessible via the company's website; teleconference dial‑in numbers and replay details are provided. An archived webcast will be available for approximately three months; a telephonic replay will be available for one week.
Veru (NASDAQ: VERU) reported fiscal 2025 results and clinical progress for enobosarm in obesity on Dec 17, 2025. Key clinical highlights include FDA regulatory clarity that a ≥5% placebo‑corrected incremental weight loss at 52 weeks or smaller weight difference with clinically meaningful physical function benefit may support approval. Phase 2b PLATEAU (enobosarm 3 mg + GLP‑1 RA) is planned to start Q1 2026 with interim analysis expected Q1 2027. Fiscal 2025 results: cash $15.8M (9/30/25), R&D $15.6M, operating loss $24.8M; company completed a post‑period public offering for ~$23.4M net proceeds.